Dynavax Technologies | DVAX - Debt

Stock Price
15.49
Daily Change
-0.02 -0.13%
Monthly
0.39%
Yearly
18.15%
Q1 Forecast
15.01

Dynavax Technologies reported $285.5M in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Adma Biologics USD 83.12M 702K Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
AstraZeneca USD 32.84B 1.19B Jun/2025
Biogen USD 6.29B 309.5M Sep/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Dynavax Technologies USD 285.5M 24.99M Jun/2025
Gilead Sciences USD 24.95B 6M Jun/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Novartis USD 32.64B 1.37B Jun/2025
Pfizer USD 60.85B 78M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
TG Therapeutics USD 245.34M 8.38M Sep/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025